TransMID Obtains Orphan-Drug Designation in Japan

Xenova Group has announced that, Sosei, its licensee for the Japanese market, has been granted orphan-drug status for the use of TransMID in the treatment of glioma (a type of brain cancer) by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

TransMID is Xenova's lead product candidate currently in Phase III trials for the treatment of glioblastoma multiforme. The achievement of orphan-drug designation triggers a milestone payment from Sosei to Xenova. Orphan-drug designation will facilitate the initiation of clinical trials by Sosei and provide fast-track approval process by the MHLW once trials have been completed and a dossier seeking marketing approval has been filed.